Assistant Professor

Department of Pharmaceutical Sciences
College of Pharmacy
Larkin University

Contact Information

Office: TBA
Office Phone: 305-760-7522

Email: KVenkata@Ularkin.org
Office Hours: TBA

Education and Training

B.Pharm.

Osmania University

Hyderabad, India

M.S. Chemistry

Illinois State University

Normal, Illinois

Ph.D. Organic Chemistry/Medicinal Chemistry

University of Southern California

Los Angeles, California

Teaching Interests 

Dr. Venkata’s teaching interest includes various Pharm. D. courses, such as Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry and Pharmacognosy/Natural Products.

Scholarly Interests

Dr. Venkata’s research interests are in the discovery and development of novel pharmaceuticals. His academic and industrial research experience was focused towards the design and development of anti-cancer, anti-inflammatory and anti-arrhythmic agents by utilizing synthetic organic chemistry and advanced spectroscopic methods. His goal is to integrate advanced computational methods with traditional basic sciences towards the development of drug-resistant infections, such as New Delhi Metallo-beta-lactamase 1 and also towards the development of new molecules for metabolic disorders, such as diabetes and obesity.

Selected Recent Publications

Patel S, Nagulapalli Venkata KC, Bhattacharyya P, Bishayee A. Potential of neem (Azadirachta indica L.) for the prevention and treatment of oncologic diseases. Seminars in Cancer Biology 40-41:100-115 (2016)

Yamaki J, Nagulapalli Venkata KC, Mandal A, Bhattacharyya P, Bishayee A. Health-promoting and disease-preventive potential of Trianthema portulacastrum Linn. (Gadabani) –  An Indian medicinal and dietary plant. Journal of Integrated Medicine 14:84-99 (2016)

Khan F, Niaz K, Maqbool F, Hassan FI, Abdollahi M, Nagulapalli Venkata KC, Nabavi SM, Bishayee A. Molecular targets underlying the anticancer effects of quercetin: An update. Nutrients 8:529 (2016) doi:10.3390/nu8090529

Ning Y, LaBonte M, Zhang W, Bohanes P, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, demonstrates antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular Cancer Therapeutics 11:1353-1364 (2012)

Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Young D, Chung HK, Choi D, LaBonte MJ, Ladner RD, Nagulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz HJ, Hong YK. Interleukin-8 and its receptor CXCR2 in the tumor microenvironment promote colon cancer growth, progression and metastasis. British Journal of Cancer 106:1833-1841 (2012)

Petasis NA, Keledjian R, Sun YP, Nagulapalli KC, Tjonahen E, Yang R, Serhan CN. Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorganic and Medicinal Chemistry Letters 18:1382-1387 (2008)

 Publication list via PubMed:

http://www.ncbi.nlm.nih.gov/pubmed/?term=Nagulapalli+Venkata+KC

Selected Recent Presentations

Nagulapalli Venkata, KC. Novel and practical method for the synthesis of indoles and other heterocycles. 243rd American Chemical Society National Meeting and Exposition, San Diego, CA, March 25-28, 2012.

Nagulapalli Venkata, KC. Synthesis-based design: A holistic approach to lead development, 243rd American Chemical Society National Meeting and Exposition, San Diego, CA, March 25-28, 2012.

Nagulapalli Venkata, KC. Targeting of CXCR2 inflammatory signaling in triple negative breast cancer, American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Washington DC, October 23-27, 2011.

Awards and Honors

Burg Foundation Postdoctoral Teaching Award

Harold Moulton Fellowship for outstanding research at University of Southern California

Member, Royal Society of Chemistry

Guest Editor, Frontiers in Chemical Biology (partnered with Nature publication house)

Editorial Board Member, Anti-inflammatory and Anti-allergy Agents in Medicinal Chemistry